Technology | PET Imaging | June 28, 2018

MILabs Introduces Futuristic PET Capabilities on New VECTor6 System

Preclinical system offers simultaneous sub-mm imaging of multiple PET, multiple PET/SPECT and virtually all radiotherapy isotopes

MILabs Introduces Futuristic PET Capabilities on New VECTor6 System

June 28, 2018 — At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia, MILabs introduced the new VECTor6 positron emission tomography (PET) system loaded with innovative features. New features incorporated in its 4x4D omni-tomography design include PET, single photon emission computed tomography (SPECT), optical and X-ray computed tomography (CT) imaging modalities.

MILabs CEO and Founder Prof. Frederik Beekman said that the company has long intended to create a multimodality imaging system that can image multiple disease tracers simultaneously at the sub-mm resolution level required to translate research from humanized mouse models to the clinic. He added that by magnifying small-animal images and collimating true tracer photon events, MILabs has improved detection sensitivity and resolution so that minute quantities of both short- and long-lived PET tracers can be imaged within the sub-mm range.

Other user applications include simultaneous sub-mm imaging of multiple PET. multiple PET/SPECT and virtually all radiotherapy isotopes.

For more information: www.milabs.com

Related Content

A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.

Figure 1. Tau accumulation over one year measured in composite A) mesial temporal ROI; and B) temporoparietal ROI in cognitively unimpaired participants (blue) and cognitively impaired participants (red). The CI group included participants with clinical mild cognitive impairment and dementia. Higher rates of tau accumulation were observed in participants on the AD continuum (CU Aβ+ve and CI Aβ+ve). Participants with the highest baseline tau and rates of tau accumulation were younger and more likely to be CI Aβ+ve. Image courtesy of SNMMI

News | PET Imaging | June 16, 2021
June 16, 2021 — A novel positron emission tomography (PET
SNMMI's Image of the Year is a detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame

Figure 1. A: COVID-19-related spatial covariance pattern of cerebral glucose metabolism overlaid onto an MRI template. Voxels with negative region weights are color-coded in cool colors, and regions with positive region weights in hot colors. B: Association between the expression of COVID-19-related covariance pattern and the Montreal Cognitive Assessment (MoCA) score adjusted for years of education. Each dot represents individual patient. C: Results of a statistical parametric mapping analysis. Upper row illustrates regions that show significant increases of normalized FDG uptake in COVID-19 patients at 6-months follow-up compared to the subacute stage (paired t test, p < 0.01, false discovery rate-corrected). Bottom row depicts regions that still show significant decreases of normalized FDG uptake in COVID-19 patients at 6-months follow-up compared to the age-matched control cohort at an exploratory statistical threshold (two-sample t test, p < 0.005). Image Credit: G Blazhenets et al., Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg

News | PET Imaging | June 16, 2021
June 16, 2021 — The effects of COVID-19 on the b
A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease — at their earliest stages, enabling physicians to diagnose and treat patients more quickly. Termed super-resolution, the imaging methodology combines position emission tomography (PET) with an external motion tracking device to create highly detailed images of the brain.

Result of the Hoffman brain phantom study. Top row: same PET slice reconstructed with A) 2mm static OSEM, B) 1mm static OSEM, C) proposed SR method and D) corresponding CT slice (note that the CT image can be treated as a high-resolution reference). Middle row: zoom on region of interest for corresponding images. Bottom row: Line profiles for corresponding data. Image created by Y Chemli, et al., Gordon Center for Medical Imaging: Department of Radiology Massachusetts General Hospital, Harvard Medical School, Boston, MA.

News | PET Imaging | June 14, 2021
June 14, 2021 — A new imaging technique has the potential to detect neurological disorders — such as...
Positron emission tomography (PET) using a 68Ga-labeled fibroblast activation protein inhibitor (FAPI) can noninvasively identify and monitor pulmonary fibrosis, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.

A) Axial CT images through the mouse lungs at 7 and 14 days after intratracheal administration of bleomycin or saline (as a control), demonstrating increased lung fibrosis in the bleomycin group (white arrows). (B) CT attenuation histograms in Hounsfield units (HU) after lung segmentation demonstrate increased attenuation in the lungs in the bleomycin group than the control group (p <0.05), consistent with increasing fibrosis (n=3). (C) Representative axial PET/CT fusion images at 20 and 60 min demonstrating increased FAPI uptake in the lungs of the bleomycin group (white arrows) with no significant uptake in the control group (yellow arrows). (D) Time-activity curve of lung uptake ROI analysis demonstrating higher FAPI uptake in the lungs of the bleomycin group than the control (p < 0.05), 14 days after bleomycin (n=3). (E) Ex vivo biodistribution data of lung tissue demonstrating higher radiotracer uptake in the lungs of the bleomycin group than the control (n=3). *p<0.05, **p<0.01. Image created by CA Ferreira et al., University of Wisconsin-Madison, Madison, WI.

News | PET-CT | June 14, 2021
June 14, 2021 — Positron emission tomography (PET) using
Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.

Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.

News | SPECT Imaging | June 14, 2021
June 14, 2021 — An advanced artificial i...
News | PET-CT | June 10, 2021
June 10, 2021 — Bringing the power of...
The U.S. Food and Drug Administration (#FDA) approved #Aduhelm (#aducanumab) for the treatment of #Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

Getty Images

News | PET Imaging | June 07, 2021
June 7, 2021 — The U.S.
According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), increased axillary lymph node or ipsilateral deltoid uptake is occasionally observed on FDG or 11C-choline PET performed after Pfizer-BioNTech or Moderna COVID-19 vaccination

(A) 57-year-old woman with right upper arm melanoma who received the first dose of the COVID-19 vaccine (Pfizer-BioNTech) in the left deltoid 15 days prior to FDG PET/CT. FDG uptake is observed within left axillary lymph nodes (arrow, SUVmax = 9.3).

(B) 62-year-old man with metastatic prostate carcinoma who received the second dose of COVID-19 vaccine (Pfizer-BioNTech) in the right deltoid 7 days prior to 11C-choline PET/CT. 11C-choline uptake is observed within right axillary lymph nodes (arrows, SUVmax = 3.1) as well as the right deltoid muscle (circle, SUVmax = 1.7).

News | Coronavirus (COVID-19) | May 19, 2021